Here, we used CRISPR/Cas9 technology to engineer tumor cells with various deletions of the ATGs, which are most frequently hit by SCNAs: BECN1, MAP1LC3B/LC3, and ATG10 [21]. The gene discussed is MAP1LC3A; the disease is neoplasm.